NORVERAPAMIL, (R)-

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H36N2O4
Molecular Weight	440.575
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1OC

InChI

InChIKey=UPKQNCPKPOLASS-AREMUKBSSA-N

InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C26H36N2O4
Molecular Weight	440.575
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.thepharmaletter.com/article/agi-finalizing-us-nda-plan-for-arverapamil | https://clinicaltrials.gov/ct2/show/NCT00552565

Arverapamil (brand name Rezular), a modulator of melatonin and serotonin receptors, was developed by Ireland-based company, AGI Therapeutics. The drug participated in phase III of clinical trials for patients to treat the irritable bowel syndrome with diarrhea, the trial was discontinued because the drug didn’t meet the primary endpoint.

Originator

Approval Year

Sample Use Guides

In Vivo Use Guide

Rezular (arverapamil) 37.5mg 3xday up to 12 weeks or Rezular 75mg 3xday up to 12 weeks

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 06:36:31 UTC 2023` Edited by `admin` on `Sat Dec 16 06:36:31 UTC 2023`
Record UNII	3J8P56R04P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NORVERAPAMIL, (R)-

Common Name

English

BENZENEACETONITRILE, .ALPHA.-(3-((2-(3,4-DIMETHOXYPHENYL)ETHYL)AMINO)PROPYL)-3,4-DIMETHOXY-.ALPHA.-(1-METHYLETHYL)-, (.ALPHA.R)-

Common Name

English

(R)-NORVERAPAMIL

Common Name

English

Code System Code Type Description

CAS

123932-43-4